AU2019312296B2 - Pyridone A2R antagonists - Google Patents
Pyridone A2R antagonists Download PDFInfo
- Publication number
- AU2019312296B2 AU2019312296B2 AU2019312296A AU2019312296A AU2019312296B2 AU 2019312296 B2 AU2019312296 B2 AU 2019312296B2 AU 2019312296 A AU2019312296 A AU 2019312296A AU 2019312296 A AU2019312296 A AU 2019312296A AU 2019312296 B2 AU2019312296 B2 AU 2019312296B2
- Authority
- AU
- Australia
- Prior art keywords
- ome
- alkyl
- group
- cancer
- a2ar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862711273P | 2018-07-27 | 2018-07-27 | |
| US62/711,273 | 2018-07-27 | ||
| PCT/US2019/043608 WO2020023846A1 (en) | 2018-07-27 | 2019-07-26 | Pyridone a2r antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019312296A1 AU2019312296A1 (en) | 2021-03-18 |
| AU2019312296B2 true AU2019312296B2 (en) | 2025-05-29 |
Family
ID=69182367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019312296A Active AU2019312296B2 (en) | 2018-07-27 | 2019-07-26 | Pyridone A2R antagonists |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12064433B2 (https=) |
| EP (1) | EP3829581B1 (https=) |
| JP (1) | JP7394831B2 (https=) |
| KR (1) | KR102809468B1 (https=) |
| CN (1) | CN112996509B (https=) |
| AU (1) | AU2019312296B2 (https=) |
| CA (1) | CA3107079A1 (https=) |
| ES (1) | ES2982326T3 (https=) |
| PL (1) | PL3829581T3 (https=) |
| WO (1) | WO2020023846A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020185859A1 (en) | 2019-03-12 | 2020-09-17 | Arcus Biosciences, Inc. | Treatment of oncogene-driven cancers |
| US12310965B2 (en) | 2019-03-29 | 2025-05-27 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
| CN115298165B (zh) | 2020-03-19 | 2024-09-17 | 艾库斯生物科学有限公司 | 作为HIF-2α抑制剂的四氢化萘和四氢喹啉化合物 |
| JP2021183587A (ja) * | 2020-05-22 | 2021-12-02 | 武田薬品工業株式会社 | 複素環化合物 |
| AU2021292195A1 (en) | 2020-06-17 | 2023-01-05 | Arcus Biosciences, Inc. | Crystalline forms of a CD73 inhibitor and uses thereof |
| KR20230062845A (ko) | 2020-09-03 | 2023-05-09 | 이뮨센서 테라퓨틱스, 인코포레이티드 | 퀴놀린 cgas 길항제 화합물 |
| JP2024506858A (ja) | 2021-02-02 | 2024-02-15 | リミナル・バイオサイエンシーズ・リミテッド | Ｇｐｒ８４アンタゴニストおよびその使用 |
| CN117295741A (zh) | 2021-05-21 | 2023-12-26 | 艾库斯生物科学有限公司 | Axl化合物 |
| JP2024521712A (ja) | 2021-05-21 | 2024-06-04 | アーカス バイオサイエンシーズ，インコーポレーテッド | Ａｘｌ阻害化合物 |
| WO2023077046A1 (en) | 2021-10-29 | 2023-05-04 | Arcus Biosciences, Inc. | Inhibitors of hif-2alpha and methods of use thereof |
| CN119137112A (zh) | 2022-03-02 | 2024-12-13 | 免疫传感器治疗股份有限公司 | 喹啉cGAS拮抗剂化合物 |
| CA3256561A1 (en) | 2022-05-02 | 2023-11-09 | Arcus Biosciences, Inc. | Anti-tigit antibodies and their uses |
| EP4554680A1 (en) | 2022-07-15 | 2025-05-21 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
| US20260028336A1 (en) | 2022-07-20 | 2026-01-29 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2024081385A1 (en) | 2022-10-14 | 2024-04-18 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
| EP4604920A1 (en) | 2022-10-20 | 2025-08-27 | Arcus Biosciences, Inc. | Lyophilized formulations of cd73 compounds |
| WO2024097736A1 (en) | 2022-11-02 | 2024-05-10 | Arcus Biosciences, Inc. | Processes for preparing azolopyrimidine compounds |
| EP4705292A1 (en) | 2023-05-05 | 2026-03-11 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| US20250011318A1 (en) | 2023-05-25 | 2025-01-09 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2025054339A1 (en) | 2023-09-08 | 2025-03-13 | Arcus Biosciences, Inc. | Triazolopyridine compounds as inhibitors of kit |
| WO2025072330A1 (en) | 2023-09-26 | 2025-04-03 | Arcus Biosciences, Inc. | Kit inhibitor compounds and methods of use thereof |
| WO2025076299A1 (en) | 2023-10-06 | 2025-04-10 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| TW202523302A (zh) | 2023-11-02 | 2025-06-16 | 美商阿克思生物科學有限公司 | 噻唑化合物及其使用方法 |
| WO2026006759A1 (en) | 2024-06-28 | 2026-01-02 | Arcus Biosciences, Inc. | Pharmaceutical compositions, dosage forms, and methods of making and using same |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070219221A1 (en) * | 2006-03-17 | 2007-09-20 | Dewan Zeng | Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists |
| WO2016126570A1 (en) * | 2015-02-06 | 2016-08-11 | Merck Sharp & Dohme Corp. | Aminoquinazoline compounds as a2a antagonist |
| WO2018136700A1 (en) * | 2017-01-20 | 2018-07-26 | Arcus Biosciences, Inc. | Azolopyrimidine for the treatment of cancer-related disorders |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7674791B2 (en) | 2003-04-09 | 2010-03-09 | Biogen Idec Ma Inc. | Triazolopyrazines and methods of making and using the same |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| WO2006091898A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Pyrazolyl substituted xanthines |
| AU2006230099B2 (en) | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
| EP2166854A4 (en) | 2007-06-13 | 2012-05-16 | Merck Sharp & Dohme | TRIAZONE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED SUFFERINGS |
| ES2776406T3 (es) | 2007-07-12 | 2020-07-30 | Gitr Inc | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
| EP2473531A4 (en) | 2009-09-03 | 2013-05-01 | Merck Sharp & Dohme | Anti-gitr antibodies |
| JP5998060B2 (ja) | 2010-03-04 | 2016-09-28 | マクロジェニクス，インコーポレーテッド | Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用 |
| PT2614082T (pt) | 2010-09-09 | 2018-12-03 | Pfizer | Moléculas de ligação a 4-1bb |
| WO2013130811A1 (en) | 2012-02-29 | 2013-09-06 | Chemocentryx, Inc. | Pyrazol-1-yl benzene sulfonamides as ccr9 antagonists |
| JP6378759B2 (ja) | 2013-07-02 | 2018-08-22 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｓｕｍｏ活性化酵素阻害剤として有用なヘテロアリール化合物 |
| CA3158951A1 (en) | 2016-08-15 | 2018-02-22 | Purdue Research Foundation | 4-substituted aminoisoquinoline derivatives |
-
2019
- 2019-07-26 US US17/263,016 patent/US12064433B2/en active Active
- 2019-07-26 AU AU2019312296A patent/AU2019312296B2/en active Active
- 2019-07-26 KR KR1020217005878A patent/KR102809468B1/ko active Active
- 2019-07-26 EP EP19841391.6A patent/EP3829581B1/en active Active
- 2019-07-26 JP JP2021504283A patent/JP7394831B2/ja active Active
- 2019-07-26 WO PCT/US2019/043608 patent/WO2020023846A1/en not_active Ceased
- 2019-07-26 CN CN201980064256.XA patent/CN112996509B/zh active Active
- 2019-07-26 PL PL19841391.6T patent/PL3829581T3/pl unknown
- 2019-07-26 ES ES19841391T patent/ES2982326T3/es active Active
- 2019-07-26 CA CA3107079A patent/CA3107079A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070219221A1 (en) * | 2006-03-17 | 2007-09-20 | Dewan Zeng | Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists |
| WO2016126570A1 (en) * | 2015-02-06 | 2016-08-11 | Merck Sharp & Dohme Corp. | Aminoquinazoline compounds as a2a antagonist |
| WO2018136700A1 (en) * | 2017-01-20 | 2018-07-26 | Arcus Biosciences, Inc. | Azolopyrimidine for the treatment of cancer-related disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021531314A (ja) | 2021-11-18 |
| ES2982326T3 (es) | 2024-10-15 |
| CN112996509A (zh) | 2021-06-18 |
| KR20210038642A (ko) | 2021-04-07 |
| EP3829581C0 (en) | 2024-04-03 |
| WO2020023846A1 (en) | 2020-01-30 |
| KR102809468B1 (ko) | 2025-05-19 |
| EP3829581A4 (en) | 2022-04-27 |
| US12064433B2 (en) | 2024-08-20 |
| EP3829581B1 (en) | 2024-04-03 |
| US20210161898A1 (en) | 2021-06-03 |
| CN112996509B (zh) | 2024-10-01 |
| AU2019312296A1 (en) | 2021-03-18 |
| PL3829581T3 (pl) | 2024-07-01 |
| JP7394831B2 (ja) | 2023-12-08 |
| EP3829581A1 (en) | 2021-06-09 |
| CA3107079A1 (en) | 2020-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019312296B2 (en) | Pyridone A2R antagonists | |
| AU2022203515B2 (en) | Azolopyrimidine for the treatment of cancer-related disorders | |
| EP3618829B1 (en) | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders | |
| EP3634417B1 (en) | Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders | |
| US12410170B2 (en) | 2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compounds | |
| AU2019379808C1 (en) | Inhibitors of ARG1 and/or ARG2 | |
| US20230024438A1 (en) | Inhibitors of hif-2alpha | |
| HK40054296B (en) | Pyridone a2r antagonists | |
| HK40054296A (en) | Pyridone a2r antagonists | |
| HK40024629A (en) | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders | |
| HK40024629B (en) | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders | |
| HK40055891A (en) | Pyridone a2r antagonists | |
| HK40027765B (en) | Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders | |
| HK40027765A (en) | Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders | |
| HK40055891B (zh) | 吡啶酮a2r拮抗剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |